This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.
18F-DCFPyL is a novel low-molecular weight PSMA imaging agent. A recent study of patients with metastatic prostate cancer found that PSMA PET/CT identified more sites of disease than conventional imaging with CT, MRI and bone scan. In this study we aim to investigate 18F-DCFPyL PET/CT in patients with an elevated PSA following radical prostatectomy. During the course of this study, patients will undergo two 18F-DCPyL PET/CT scans. The first scan will take place within 45 days of staging imaging and the second will take place following six months of standard of care therapy.
Age ≥18 years History of adenocarcinoma of the prostate treated with radical prostatectomy Serum PSA level ≥0.2 ng/mL at least 45 days prior to study enrollment Completed staging evaluation with bone scan as well as CT or MRI of the abdomen and pelvis at least 45 days prior to study enrollment
Exclusion Criteria:
Intention to enroll in a blinded therapeutic clinical trial History of other malignancy diagnosed within the last three years (the exception of squamous cell or basal cell carcinoma of the skin)
